期刊文献+

过氧化物酶体增殖因子活化受体(PPARs)激动剂治疗Ⅱ型糖尿病的研究进展 被引量:4

Research on peroxisome-proliferator-activated-receptor(PPARs) agonists to therapy type 2 diabetes mellitus
原文传递
导出
摘要 过氧化物酶体增殖因子活化受体(peroxisome proliferator-activated receptor,PPARs)是核激素受体家族中配体激活受体,主要影响糖尿病的靶蛋白,可以调控葡萄糖、胆固醇及脂代谢紊乱。本文综述了PPARs的结构、分类及其功能,并对单一受体激动剂及PPARα/γ双重激动剂研究进展进行综述。 Peroxisome proliferator-activated receptor(PPARs) are ligand-activated receptor in the family of nuclear hormone receptors,and regulate glucose,cholesterol and cholesterol metabolic disorders as the target protein. In this paper,the structure,classification and function of PPARs were reviewed. The progress of PPARα agonists,PPARγ agonists and PPARα/γ double agonists were introduced in detail.
作者 梁晓霞 赵慧敏 马宇衡 张振涛 YU Pan;LI Dong-dong;XIAO Wei;ZHAO Lin-guo(Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University , Nanfing 210037, China;College of Chemical Engineering ,Nanjing Forestry University ,Nanjing 210037, China;Jiangsu Kanion Pharmaceutical Co. ,Ltd. ,Lianyungang 222001, China)
出处 《中国药物化学杂志》 CAS CSCD 北大核心 2018年第2期157-163,共7页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金项目(21562033)
关键词 过氧化物酶体增长因子活化受体 激动剂 糖尿病 peroxisome-proliferator-activated-receptor(PPARs) agonists diabetes mellitus
作者简介 梁晓霞(1993-),女(汉族),山西朔州人,硕士研究生,E—mail:653997805@qq.com;;马宇衡(1980-),男(汉族),内蒙古包头人,副教授,硕士生导师,主要从事抗肿瘤药物的研究,Tel:(0471)6653132,E-mail:myhstar@126.com。;通信作者:张振涛(1961-),男(汉族),河北石家庄人,教授,硕士生导师,主要从事先导化合物结构改造的研究,Tel:(0471)6653216,E-mail:857805364@qq.com;
  • 相关文献

参考文献6

二级参考文献189

  • 1CHEOM H G, KIM S S, KIM K R, et al. Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold[ J ]. Biochem Pharmacol, 2005, 70(1) :22-29.
  • 2SAKASHITA H,AKAHOSHI F, KITAJIMA H,et al.[ (S) -c-( Arylamino ) prolyl ] thiazolidine compounds as a novel series of potent and stable DPP-Ⅳ inhibi- tots[J]. Bioorg Med Chem, 2006, 14 ( 11 ) :3662 - 3671.
  • 3KONDO T,SUGIMOTO I,NEKADO T,et al. Design and synthesis of long-acting inhibitors of dipeptidyl peptidase Ⅳ [J]. Bioorg Med Chem,2007,15 (5) : 2715 - 2735.
  • 4DEACON C F, HOIST J J. Dipeptidyl peptidase Ⅳ inhibitors:a promising new therapeutic approach for the management of type 2 diabetes[J]. Int J Biochem Cell Biol,2006,38(5/6) :831 -844.
  • 5KING L C, HLAVACEK R J. The reaction of ketone with iodine and thiourea[ J ]. J Am Chem Soc, 1950, 72 (8) :3722 - 3725.
  • 6FUKUSHIMA H, HIRATATE A, TAKAHASHI M, et al. Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl Feptidase Ⅳ inhibitors[ J]. Bioorg Med Chem,2004, 12(23) :6053 -6061.
  • 7HULIN B, CABRAL S, LOPAZE M G, et al. New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase Ⅳ inhibitors [ J ]. Bioorg Med Chem Lett,2005,15 (21) :4770 -4773.
  • 8[1]Michalik L,Wahli W.Peroxisome proliferator-activated receptors:three isotypes for a multitude of functions[J].Curr Opin Biotechnol,1999,10(6):564-570.
  • 9[2]Issemann I,Green S.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators[J].Nature,1990,347(6294):645-650.
  • 10[3]Kliewer SA,Umesono K,Noonan DJ,et al.Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors[J].Nature,1992,358(6389):771-774.

共引文献28

同被引文献43

引证文献4

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部